ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
March 15, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab...
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis
January 20, 2022 16:05 ET
|
ASLAN PHARMACEUTICALS LIMITED
The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13...
ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004
January 18, 2022 08:06 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Management to host the second webinar in ASLAN’s A4 series on Thursday, January 20, 2022, at 12:00pm ET MENLO PARK, Calif., and SINGAPORE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- ASLAN...
ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences
January 11, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Data from Phase 1b dose escalation cohorts to be presented during the 2022 Winter Clinical Dermatology Conference, held in-person from 14-19 January, 2022, in Koloa, Hawaii - Data will also be...
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022
January 06, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
December 06, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
November 22, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Nov. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021
November 10, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
October 26, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN004 met primary endpoint and key secondary efficacy endpoints in a Phase 1 Multiple-Ascending-Dose (MAD) trial in patients with moderate-to-severe atopic dermatitis (AD) On track to initiate...
ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers
October 22, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Oct. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...